SCHEMBL2809482

SCHEMBL2809482

COc1ccc(CN2CCc3nn(C)c4nc(NCCCN5CCCC5=O)nc2c34)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 4/20 0.44
TYRO3 Q06418 3/20 0.44
MAPT P10636 2/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RECQL P46063 1/20 0.44
KMT2A Q03164 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
GAA P10253 2/20 0.43
HSD17B10 Q99714 2/20 0.43
PGK1 P00558 1/20 0.41
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814728 0.90 RCE1 (0.42) SMN1; SMN2ALDH1A1TYRO3MAPTKDM4E
SCHEMBL13131652 0.86 SHMT2 (0.48) MAPTKDM4ECYP3A4CYP2C19KMT2A
SCHEMBL2814487 0.85 BCDIN3D (0.40) SMN1; SMN2ALDH1A1MAPTCYP1A2CYP3A4
SCHEMBL2812150 0.82 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL2809950 0.82 BCDIN3D (0.38) SMN1; SMN2MAPTCYP3A4KMT2AGAA
SCHEMBL2812452 0.81 TP53 (0.41) SMN1; SMN2TYRO3MAPTKMT2AGAA
SCHEMBL2809534 0.81 MAPT (0.40) SMN1; SMN2ALDH1A1MAPTKDM4ECYP1A2
SCHEMBL2812793 0.81 HRH1 (0.47) MAPTKMT2A
SCHEMBL2809862 0.80 PIK3CA (0.47) SMN1; SMN2ALDH1A1MAPTKDM4EHPGD
SCHEMBL2809426 0.80 HRH1 (0.39) ALDH1A1MAPTKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 SMN1; SMN2 2524/4885ALDH1A1 924/4885TYRO3 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.